High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer-Reference-Cited by-同舟云学术

High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer

Published:2023-08 Issue: Volume:51 Page:101884
ISSN:1748-0132
Container-title:Nano Today
language:en
Short-container-title:Nano Today

Author:

Lim Chaemin,Hwang Duhyeong,Yazdimamaghani Mostafa,Atkins Hannah Marie,Hyun Hyesun,Shin Yuseon,Ramsey Jacob D.,Rädler Patrick D.,Mott Kevin R.,Perou Charles M.,Sokolsky-Papkov Marina,Kabanov Alexander V.

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Bioengineering,Biotechnology

Reference83 articles.

1. Triple-Negative Breast Cancer: Risk Factors to Potential Targets

2. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

3. Triple-negative breast cancer molecular subtyping and treatment progress

4. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

5. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy;Biomaterials;2025-01

2. Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach;International Journal of Pharmaceutics;2024-09

3. Nanovaccine of tumor-derived antigenic microparticles for enhancing effect of arsenic trioxide in cancer immunotherapy;Nano Today;2024-08

4. Self‐Nanoformulating Poly(2‐oxazoline) and Poly(2‐oxazine) Copolymers Based Amorphous Solid Dispersions as Microneedle Patch: A Formulation Study;Advanced Materials Technologies;2024-07-23

5. Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple‐negative breast cancer;Bioengineering & Translational Medicine;2024-06-04